apm_com
1 week ago
Perhaps a little insight from a competitor on Q2 activity and 2nd half potential:
Evolus to Report Second Quarter Financial Results on July 31, 2024
Business Wire
NEWPORT BEACH, Calif.-(BUSINESS WIRE) --Evolus, Inc. (EOLS.NaE), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after the U.S. financial markets close.
Evolus (EOLS.NaE) management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks.
To participate in the conference call, dial (877) 407-6184 (U.S.)
ASPRV
2 weeks ago
Is there an alternative method to forecast Daxxify revenue aside from monitoring Instagram or TikTok trends?
I'm frustrated with the volatility following earnings reports.
I recently acquired additional shares at $2.80, but this hasn't significantly lowered my average price.
Additionally, I am puzzled by the substantial increase in AEON's stock price. In my opinion, there is little to anticipate from CD, given its comparable duration to Botox. Furthermore, they were unsuccessful in the migraine market.